Beig A - Search Results

1

Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay.

Beig A, Miller JM, Lindley D, Carr RA, Zocharski P, Agbaria R, Dahan A. Beig A, et al. J Pharm Sci. 2015 Sep;104(9):2941-7. doi: 10.1002/jps.24496. Epub 2015 May 18. J Pharm Sci. 2015. PMID: 25989509

2

The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.

Miller JM, Beig A, Carr RA, Webster GK, Dahan A. Miller JM, et al. Among authors: beig a. Mol Pharm. 2012 Mar 5;9(3):581-90. doi: 10.1021/mp200460u. Epub 2012 Feb 22. Mol Pharm. 2012. PMID: 22280478

3

Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption.

Beig A, Miller JM, Dahan A. Beig A, et al. Eur J Pharm Biopharm. 2012 Jun;81(2):386-91. doi: 10.1016/j.ejpb.2012.02.012. Epub 2012 Feb 24. Eur J Pharm Biopharm. 2012. PMID: 22387337

4

The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.

Dahan A, Beig A, Ioffe-Dahan V, Agbaria R, Miller JM. Dahan A, et al. Among authors: beig a. AAPS J. 2013 Apr;15(2):347-53. doi: 10.1208/s12248-012-9445-3. Epub 2012 Dec 15. AAPS J. 2013. PMID: 23242514 Free PMC article.

5

The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off.

Beig A, Miller JM, Dahan A. Beig A, et al. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1293-9. doi: 10.1016/j.ejpb.2013.05.018. Epub 2013 Jun 11. Eur J Pharm Biopharm. 2013. PMID: 23770429

6

Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.

Beig A, Agbaria R, Dahan A. Beig A, et al. PLoS One. 2013 Jul 16;8(7):e68237. doi: 10.1371/journal.pone.0068237. Print 2013. PLoS One. 2013. PMID: 23874557 Free PMC article.

7

The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility-permeability interplay.

Beig A, Agbaria R, Dahan A. Beig A, et al. Eur J Pharm Sci. 2015 Sep 18;77:73-8. doi: 10.1016/j.ejps.2015.05.024. Epub 2015 May 22. Eur J Pharm Sci. 2015. PMID: 26006306

8

The solubility-permeability interplay and oral drug formulation design: Two heads are better than one.

Dahan A, Beig A, Lindley D, Miller JM. Dahan A, et al. Among authors: beig a. Adv Drug Deliv Rev. 2016 Jun 1;101:99-107. doi: 10.1016/j.addr.2016.04.018. Epub 2016 Apr 26. Adv Drug Deliv Rev. 2016. PMID: 27129443 Review.

9

Hydrotropic Solubilization of Lipophilic Drugs for Oral Delivery: The Effects of Urea and Nicotinamide on Carbamazepine Solubility-Permeability Interplay.

Beig A, Lindley D, Miller JM, Agbaria R, Dahan A. Beig A, et al. Front Pharmacol. 2016 Oct 25;7:379. doi: 10.3389/fphar.2016.00379. eCollection 2016. Front Pharmacol. 2016. PMID: 27826241 Free PMC article.

10

Striking the Optimal Solubility-Permeability Balance in Oral Formulation Development for Lipophilic Drugs: Maximizing Carbamazepine Blood Levels.

Beig A, Miller JM, Lindley D, Dahan A. Beig A, et al. Mol Pharm. 2017 Jan 3;14(1):319-327. doi: 10.1021/acs.molpharmaceut.6b00967. Epub 2016 Dec 16. Mol Pharm. 2017. PMID: 27981848

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters